ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes (ESTEEM)
Pre-eclampsia, Obesity, Raised Lipids
About this trial
This is an interventional prevention trial for Pre-eclampsia focused on measuring Pre-eclampsia, Gestational diabetes, Stillbirth, Small for gestational age, Admission to neonatal intensive care unit, Obesity, Raised Lipids, High Blood Pressure, Cardiovascular risk, Insulin resistance, Mediterranean dietary pattern, Dietary interventions
Eligibility Criteria
Inclusion Criteria: Pregnant women less than 18 weeks of gestation with at least one of the following:
i. BMI ≥30 Kg/m2 ii. Raised serum triglycerides ≥1.7 mmol/l iii. Raised blood pressure of systole ≥140 mm Hg or diastole ≥90 mm Hg
Exclusion Criteria:
i. BMI <18.5 Kg/m2or ≥40 Kg/m2 ii. Women on lipid altering drugs iii. History of diabetes iv. Chronic renal disease v. Auto immune disease vi. Multiple pregnancy vii. Poor understanding of written and spoken English viii. Not able to follow Mediterranean diet for religious or other reasons ix. <16 years of age x. Not able to consume nuts or extra virgin olive oil
Sites / Locations
- Barts Health NHS Trust
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
No Intervention
Other
Targeted ESTEEM diet
Current clinical practice
Non-randomised cohort
The ESTEEM dietary pattern is similar to that in a Mediterranean diet associated with reduced risk of pre-eclampsia. The intervention will include structured meal plans and grocery lists, recipes for healthy diet and appropriate choices at restaurants
The control group will be provided the usual antenatal dietary advice. This includes advice on healthy and physical activity in women with normal weight and obesity and overweight. Folic acid and vit D supplementation are provided as per national recommendations. Participants will provide outcome data at point of delivery and food frequency questionnaire at baseline and 36 weeks or delivery depending on which is sooner.
Non-randomised cohort of women with no metabolic risk factors will be followed up to delivery to collect outcome data